(Total Views: 1119)
Posted On: 12/08/2020 6:46:23 AM
Post# of 153903
Re: SizzlChest #67232
Summarized here:
"The third expected EUA is from CytoDyn Inc. (OTCMKTS: CYDY). This is a repurposed monoclonal antibody that is the only remaining phase 3 drug candidate with a mortality benefit that has not had to resize its study after meeting an interim checkpoint. This drug has a stellar safety profile with over a thousand patients and no SAE’s related to the drug. It is an anomaly because leronlimab showed it actually reduced the side effects over placebo by as much as 60% in a phase 2 mild to moderate study. Now that’s a safe drug! The company is hosting an investor update on Thursday December 10, 2020 and may be close to finishing its trial. "
"The third expected EUA is from CytoDyn Inc. (OTCMKTS: CYDY). This is a repurposed monoclonal antibody that is the only remaining phase 3 drug candidate with a mortality benefit that has not had to resize its study after meeting an interim checkpoint. This drug has a stellar safety profile with over a thousand patients and no SAE’s related to the drug. It is an anomaly because leronlimab showed it actually reduced the side effects over placebo by as much as 60% in a phase 2 mild to moderate study. Now that’s a safe drug! The company is hosting an investor update on Thursday December 10, 2020 and may be close to finishing its trial. "
(10)
(0)
